Sumanta K. Pal, MD, FASCO (@montypal) ranks #6 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 77 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: LITESPARK-011, XmAb819, CARE1. CMS Open Payments lists $1,010 in 2025 general payments.
At a Glance
- 6 posts naming a trial in 2026
- 8 trials discussed by name
- GU Cancer: US #6, Global #10 · 77 physicians engaged
- Leading physician voice: #2 of 6 physicians on CARE1; #3 of 39 physicians on TALAPRO-3
- Presented at ESMO 2026 in 2026
- CMS Open Payments lists $1,010 in 2025 general payments.
This Month
What Sumanta K. Pal, MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
Could not agree with you more @HHammersMD! This is very exciting. Looking forward to taking #XMab819 into earlier lines - I have been pushing for availability of a cohort for pts post-nivo/ipi & it is now open! https://t.co/bRtab78R2G
Brilliant discussion by @ZaydTippu, tying together #ESMO26 abstracts from @AlbigesL, @VincentWenxinXu & @DrDanielHeng. Not easy to weave between abstracts pertaining to PD-L1 assessment in #CARE1, #KIM1 in #COSMIC313 & #HRQOL in #LITESPARK11, but he pulls together a very cohesive story. Definitely worth a watch! @OncoAlert
Great presentation by @DrDanielHeng at #ESMO26 on #LITESPARK11. Congrats on simultaneous publication of the data in @Annals_Oncology! It’s a high bar to advance therapies in the 2nd line setting. I tend to still favor monotherapy for most - have had challenges with Len 20 & also want to understand more about the cardiac tox. Still, always eager to have more options to discuss with my patients! @OncoAlert
Interesting data from @DrChoueiri @DanaFarber from #LITESPARK12. Seems as though we have reached the max in what we can do with combining current classes of tx frontline. Need to see if we can incorporate novel tx upfront! #ESMO26 @brian_rini @tompowles1 @AlbigesL @OncoAlert https://t.co/KGNrgz1wcF
Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert
Who Amplifies Sumanta K. Pal, MD, FASCO
Physicians who reposted Sumanta K. Pal, MD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #6 | #10 | 77 | 122 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Sumanta K. Pal, MD, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Proffered paperPhase 1 Results of XmAb819, a Novel ENPP3 x CD3 Bispecific, in Advanced Clear Cell Renal Cell CarcinomaSource: @urotoday on X ↗
What Colleagues Are Saying About Sumanta K. Pal, MD, FASCO
2026 posts by fellow physicians that mention @montypal, quoted word for word.
Well well well… This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape! 45% response in heavily pretreated pts. Highly impressive! Needs to move into frontline combinations! Congrats @montypal + colleagues https://t.co/Did7JbvAES
Novel T-cell engager in RCC! @montypal presents exciting data from XmAb819 Ph.I (ENPP3×CD3) in heavily pretreated ccRCC. ORR 27%, DCR 68% (n=60), including prior HIF-2α exposure (ORR 26%). Grade ≥3 TRAEs 61%; discontinuation 7%. Early activity beyond IO/TKI/HIF-2α. #ESMO26 #RCC @myESMO @OncoAlert
Looking forward to joining the @OncBrothers & dear friends @apolo_andrea @montypal for this #ASCO26 adjacent discussion on Sat evening! https://t.co/DxLNicgAfJ
Congratulations @montypal on successfully introducing a novel bispecific in advanced #ccRCC - encouraging results in a heavily pretreated population https://t.co/BjiIGvx4Rw
Leveraging ENPP3 expression on RCC - @montypal presents the results of the ph I trial of ENPP3 x CD3 bispecific Cytokine-related adverse events occur mostly in early cycles Super promising antitumor activity with signs of durability so far #ESMO26 @OncoAlert https://t.co/lRDXz4btwY
XmAb819 shows impressive activity in mRCC from a phase I trial. Great job @montypal and team! @OncoAlert #ESMO26 https://t.co/OUIVwDaeLG
Trials Sumanta K. Pal, MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| LITESPARK-011 | 2 | #6 of 37 | Oct 26, 2026 |
| XmAb819 | 1 | #5 of 15 | Oct 27, 2026 |
| CARE1 | 1 | #2 of 6 | Oct 26, 2026 |
| LITESPARK-012 | 1 | #4 of 21 | Oct 25, 2026 |
| DASL-HiCaP (ANZUP1801) | 1 | #8 of 28 | Oct 23, 2026 |
| DeLLphi-305 | 1 | #21 of 86 | Oct 23, 2026 |
| VOLGA | 1 | #15 of 57 | Oct 23, 2026 |
| TALAPRO-3 | 1 | #3 of 39 | May 30, 2026 |
Sumanta K. Pal, MD, FASCO on LITESPARK-011
Brilliant discussion by @ZaydTippu, tying together #ESMO26 abstracts from @AlbigesL, @VincentWenxinXu & @DrDanielHeng. Not easy to weave between abstracts pertaining to PD-L1 assessment in #CARE1, #KIM1 in #COSMIC313 & #HRQOL in #LITESPARK11, but he pulls together a very cohesive story. Definitely worth a watch! @OncoAlert
Great presentation by @DrDanielHeng at #ESMO26 on #LITESPARK11. Congrats on simultaneous publication of the data in @Annals_Oncology! It’s a high bar to advance therapies in the 2nd line setting. I tend to still favor monotherapy for most - have had challenges with Len 20 & also want to understand more about the cardiac tox. Still, always eager to have more options to discuss with my patients! @OncoAlert
Sumanta K. Pal, MD, FASCO on XmAb819
Could not agree with you more @HHammersMD! This is very exciting. Looking forward to taking #XMab819 into earlier lines - I have been pushing for availability of a cohort for pts post-nivo/ipi & it is now open! https://t.co/bRtab78R2G
Sumanta K. Pal, MD, FASCO on CARE1
Brilliant discussion by @ZaydTippu, tying together #ESMO26 abstracts from @AlbigesL, @VincentWenxinXu & @DrDanielHeng. Not easy to weave between abstracts pertaining to PD-L1 assessment in #CARE1, #KIM1 in #COSMIC313 & #HRQOL in #LITESPARK11, but he pulls together a very cohesive story. Definitely worth a watch! @OncoAlert
Sumanta K. Pal, MD, FASCO on LITESPARK-012
Interesting data from @DrChoueiri @DanaFarber from #LITESPARK12. Seems as though we have reached the max in what we can do with combining current classes of tx frontline. Need to see if we can incorporate novel tx upfront! #ESMO26 @brian_rini @tompowles1 @AlbigesL @OncoAlert https://t.co/KGNrgz1wcF
Sumanta K. Pal, MD, FASCO on DASL-HiCaP (ANZUP1801)
Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert
Sumanta K. Pal, MD, FASCO on DeLLphi-305
Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert
Sumanta K. Pal, MD, FASCO on VOLGA
Arriving at #ESMO26 tomorrow just in time for what promises to be one of the most exciting sessions: Presidential Session #1. #INTerpath-001 presented by @ProfGLongMIA, #VOLGA by @tompowles1, #DeLLphi-305 by @sands_jacob & #DASLHiCaP by @niazi_Dr7. A terrific slate of discussants as well, incl @StephenVLiu (one of the most talented orators in our field, IMHO), @MichvdHeijden, @Silke_Gillessen & more. Hats off to @YJanjigianMD, @FAndreMD, @Prof_Nadia_H & #DrJamesLarkin for assembling a powerhouse program! @OncoAlert
Sumanta K. Pal, MD, FASCO on TALAPRO-3
Cheers to @neerajaiims on his presentation of the #TALAPRO3 data w simultaneous @NEJM publication! It reflects the dream of many clinical investigators in #oncology - to lead a trial & generate paradigm shifting data in a field that you have devoted your life to (in this case, #prostatecancer). If you see him at #ASCO26, inquire about his remarkable story. At @huntsmancancer, he built the GU program from scratch into one of the highest performing programs worldwide. He did this over the span of nearly two decades through mentorship of his faculty & fellows (@umangtalking @maughanonc @ziremozay @ggebraelmd et al), extensive outreach to the local community & active participation & leadership in multiple studies (a mix of industry, ISTs & @SWOG). Simply amazing.
Sumanta K. Pal, MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Proud of @NazliDizman @DanaFarber for a brilliant oral presentation at #ASCO26 that highlights the distribution & contribution of IMG oncologists to cancer care. @neerajaiims @DrChoueiri @shilpaonc @BradMcG04 @VincentWenxinXu @ASCOPres https://t.co/WCsTyZZi9A
For those not as familiar with the @ASCO Daily News Podcast, this is a great one to start with! Cheers to @KimmieNgMD for a brilliant conversation that led to an Award of Distinction on @commawards! @GCarroll147 @cityofhope @danafarber #ASCO26 https://t.co/768ruu8yVH
Brilliant work, @AndreaNecchi, in presenting data from CG +/- nivo in MIBC at #ESMO26. Certainly the most interesting aspect of this is derived from the rich ctNDA data associated with this study. Bravo! @PGrivasMDPhD @UroDocAsh @shilpaonc @SpiessPhilippe https://t.co/JxKPp5az6a
Leave it to @chadinabhan to pull together an exceptional group of faculty on Monday night at #ASCO26! Looking fwd to joining @DrRanaMcKay & @PGrivasMDPhD to discuss the latest developments in GU oncology - then, @VKaklamani, @stolaney1, #GregVidalMD & #JoyceOShaughnessyMD talk #breastcancer. Terrific faculty for GI, #lungcancer, #melanoma, & #braintumors as well - @DrSapnaPatel, @VivekSubbiah, @YJanjigianMD, @GIcancerDoc & so many more! Join us!
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Industry Payments
CMS Open Payments · 2025 general payments
$1,010 across 9 payments